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Abstract
Background: Each day, millions of health consumers seek drug-related information on the Web. Despite some
efforts in linking related resources, drug information is largely scattered in a wide variety of websites of different
quality and credibility.
Methods: As a step toward providing users with integrated access to multiple trustworthy drug resources, we aim
to develop a method capable of identifying drug’s dosage form information in addition to drug name recognition.
We developed rules and patterns for identifying dosage forms from different sections of full-text drug monographs,
and subsequently normalized them to standardized RxNorm dosage forms.
Results: Our method represents a significant improvement compared with a baseline lookup approach, achieving
overall macro-averaged Precision of 80%, Recall of 98%, and F-Measure of 85%.
Conclusions: We successfully developed an automatic approach for drug dosage form identification, which is
critical for building links between different drug-related resources.
Background
Seeking drug-related information is one of the major
activities of today’s online healthcare professionals and
consumers. To date, there are a wide variety of different
drug-related resources including but not limited to: the
biomedical literature in PubMed
® [1], clinical trials in
ClinicalTrial.gov [2], adverse drug effects in FDA’s
Spontaneous Reporting System, and consumer-level
drug monographs in MedlinePlus
® [3] and PubMed
Health [4]. Owing to the heterogeneous nature of each
individual resource, they are not currently linked to
each other. On the other hand, their contents are often
complementary to each other so that users would bene-
fit from an integrated access to all sources relevant to a
single drug. Thus, this poses an increasing need to build
cross-links between these different resources for the
same drug entity so that users from one site can be
informed by relevant information in other sites. To this
end, a critical step is to be able to identify the drug
entity from the corresponding narrative text.
Biomedical named entity recognition (NER) is a chal-
lenging task but it serves as a prerequisite for many
subsequent tasks like relationship extraction [5]. Over
the years, most NER tools have been developed for
automatically recognizing gene and gene products from
free text using one of the three approaches: dictionary-
based, rule-based, and machine-learning based. By con-
trast, less work involved drug entity identification.
P a r t l y ,t h i sm a yb ed u et ot h edifficulty in defining a
drug entity in text. In the earlier work that involved
automatic drug entity identification [6-9], a drug was
simply defined by its generic name/active ingredient.
Such approximation may be appropriate for those appli-
cations but to formally define a drug, other important
specifications should be considered. For instance, a
drug’s dosage form (DF) indicates the physical form in
which a drug is produced and dispensed. It is one of the
most important specifications of a drug because it
affects the way a drug is administrated in a patient.
Drugs with the same ingredients but in different dosage
forms can have different uses. For example, if timolol
comes as ophthalmic solution (eye drops), it is used to
treat glaucoma. If timolol c o m e sa sa no r a lt a b l e t ,i ti s
used to treat high blood pressure, to improve survival
after a heart attack, and to prevent migraine headaches.
Furthermore, dosage forms affect drug absorption and
drug distribution in the human body. So in order to
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pharmacokinetic and pharmacodynamic properties
should be modeled and experimented across different
dosage forms. For example, tacrolimus, a macrolide with
potent immunosuppressive effects, can come as oral
capsule and injectable solution. Its pharmacokinetic
properties were studied across intravenous, oral, and
intramuscular dosage forms [10]. Because of the impor-
tance of dosage form in drug development and con-
sumption, it is crucial to provide accurate dosage form
information in drug-related information resources.
Therefore, the goal of this work is to automatically iden-
tify drug dosage form information from free text and
subsequently normalize it using a standardized
nomenclature.
O u rp r o p o s e dm e t h o di sr u l e - b a s e da n di sr e l a t e dt o
two particular areas of previous studies. In the work of
clinical drug normalization, Peters et al., examined the
complexity, ambiguity and variability of clinical drugs (e.
g., ‘Metoprolol Succinate 200 mg sa Tab’) [11]. They
processed the clinical name as a string, and defined a
set of rules like expanding abbreviations (e.g., tab to
tablet) to normalize it. However, in their study, dosage
form was not segmented from the clinical drug name
for further normalization. The other related area is med-
ication information extraction for clinical narratives in
electronic medical records (EMRs). Recent studies have
focused on extracting both drug names and related attri-
butes such as strength, route, frequency, form, and
duration. In 2009, the task of i2b2 challenge was to
identify mentions of drugs and drug-related information
like dosages and routes of administration from discharge
summaries [12]. However, there was no requirement for
normalizing mentions to any standardized nomencla-
ture. More recently, several Natural Language Proces-
sing (NLP) systems such as MedEx [13] and MTERMS
[14] have been developed to automatically normalize
identified drugs to concepts in one or multiple terminol-
ogies. These research efforts contribute to the field of
automated medication reconciliation across the care
continuum [15,16]. They successfully applied NLP tech-
niques to summarize and encode the medication data
with high performance (F-Measure > 90%). In these sys-
tems, mentions of drug dosage form are captured from
clinical narratives but not further normalized to a stan-
dard controlled vocabulary.
In this study, we present a computational method to
identify dosage forms from full-text drug monographs,
and normalize them to a standardized nomenclature.
Specifically, we used the American Hospital Formulary
Service
® (AHFS) drug monographs provided by the
American Society of Health-system Pharmacists
®
(ASHP) as our corpus and RxNorm [17] as the standar-
dized nomenclature. To our best knowledge, this is the
first work on drug dosage form identification and nor-
malization. For evaluation, we first randomly selected
approximately 10% of the AHFS drug monographs and
produced human annotations (the gold standard). In
addition, to evaluate our method on the entire test data,
we further developed a silver standard by automatically
extracting the known dosage forms from the drug pro-
ducts that are currently listed in the drug monographs.
Methods
In Figure 1, we show an overview of our working flow
for dosage form identification and normalization. We
first processed RxNorm by encoding a dosage form hier-
archical tree DFtree and by establishing dosage form-
brand name relationships DFtree-RxBRD.S e c o n d ,w e
processed each AHFS drug monograph in XML and
extracted both the title and sentences mentioning
dosage forms in the body of a monograph. From the
title and extracted sentences, we identified dosage forms
and mapped them to RxNorm concepts. Third, we con-
structed a silver standard for evaluating the performance
of dosage form identification. Finally, we used the Preci-
sion, Recall,a n dF-Measure as evaluation metrics. The
details of each component in our method will be
explained in this section.
Processing RxNorm
RxNorm from the NLM is a standardized nomenclature
for clinical drugs and drug delivery devices [17]. In
RxNorm, a clinical drug name connects to its ingredi-
ents, strengths, and/or dosage forms through a well-
defined set of relationships, also known as Term Types
(TTY). For example, a clinical drug ‘Acetaminophen 500
MG Chewable Tablet’ in RxNorm is connected to its
ingredient (TTY = IN) ‘Acetaminophen’, its dosage form
(TTY = DF) ‘Chewable Tablet’, and its brand name
(TTY = BN) ‘Tylenol’.
In this study, we used the RxNorm data in its full
monthly release on February 7, 2011. It consists of 100
active dosage forms identified by RxNorm concept iden-
tifier (RXCUI). According to their relationship repre-
sented in the RxNorm’s dosage form definition page
[18], we manually encoded and created a hierarchical
tree structure called DFtree (see complete DFtree in
Additional File 1). As shown in Figure 2, each dosage
form is assigned a specific number to indicate its rela-
tive location in the tree. The closer a dosage form is to
the root, the more general the concept is. ‘F4’ stands for
‘Solid’, ‘F4.23’ for ‘Tablet’, ‘F4.23.1’ for ‘Oral Tablet’, and
‘F4.23.2’ for ‘Vaginal Tablet’.N o t et h a ta nR x N o r m
dosage form may be associated with more than one tree
number. For example, ‘Extended Release Enteric Coated
Tablet’ is defined in RxNorm as an enteric coated tablet
with a slowed delivery system that allows medication to
Li and Lu BMC Medical Informatics and Decision Making 2012, 12:9
http://www.biomedcentral.com/1472-6947/12/9
Page 2 of 9be released over an extended period of time at a con-
trolled rate. It has two tree numbers ‘F4.23.1.4.1’ and
‘F4.23.1.5.1’, where the former refers to its relationship
to ‘F4.23.1.4’ for ‘Enteric Coated Tablet’ and the latter to
‘F4.23.1.5’ for ‘Extended Release Tablet’. Because of
these tree numbers, we were able to automatically deter-
mine the specificity of a given dosage form.
Identifying dosage forms from AHFS drug monographs
AHFS drug monographs represent a tested and proven
source of comparative, unbiased, and evidence-based
drug information [19]. These full-text monographs, an
officially recognized federal standard on drug therapy,
have become the major drug information resource of
healthcare information systems and public health web
sites, such as First DataBank [20], MedlinePlus
® [3] and
PubMed Health [4]. These monographs are widely
viewed and used by healthcare professionals (e.g., phar-
macists, physicians, and nurses) and consumers.
Each AHFS drug monograph is subject to a drug’s
generic name/active ingredient (e.g., ‘acetaminophen’)
rather than its specific drug product (e.g., ‘Tylenol
®’).
Each monograph contains comprehensive clinical drug
descriptions in separated sections, including ‘Why is this
medication prescribed?’, ‘How should this medicine be
used?’, ‘What side effects can this medication cause?’,
Assess Precision, Recall, and F-Measure
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Figure 1 Workflow for dosage form identification and performance evaluation. Abbreviations: IN: Ingredients; BN: Brand Name; SCDF:
Semantic Clinical Drug Form; SBD: Semantic Branded Drug Form; DF: Dosage Form.
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Page 3 of 9‘Brand names’ and etc. Figure 3 shows an example
AHFS monograph ‘Acetaminophen’ in MedlinePlus
®,a
publicly accessible health-related web site developed by
the National Library of Medicine
® (NLM). In this study,
we collected the most recent 1095 AHFS drug mono-
graphs (as of January, 2011). About half (547) of the
monographs were devoted for system development and
the other half for testing.
To identify dosage forms from the full-text AHFS
drug monographs, three sections including ‘title’, ‘How
should this medicine be used?’ and ‘About your treat-
ment’ were parsed from the monograph XML files.
1 Segmenting title into ingredient and route
AHFS monograph title indicates the clinical drug dis-
cussed in the monograph. By design, the title follows
the following pattern:
I{i1,i2, ...im} + R{r1,r2, ...rn}
Where I is a set of ingredients, and R is an optional
set of administration routes such as ‘Topical’. For exam-
ple, an ingredient ‘Diclofenac’ is discussed in four drug
monographs entitled ‘Diclofenac’, ‘Diclofenac Ophthal-
mic’, ‘Diclofenac Topical’ and ‘Diclofenac Transdermal’.
To segment a title into I and R, we manually created a
list of route-indicating terms (e.g., ‘nasal’, ‘ophthalmic’,
‘otic’, ‘oral’, ‘rectal’, and ‘vaginal’) through examining the
monograph titles in the development set. These route-
indicting terms were used as marker terms. Given a title
containing N terms {t1,t 2,. . .t N}, if the position of the
most left marker term is q,t h e n{t1,...tq-1} is segmented
as ingredient I, and {tq...t N} is as route R.
2 Extracting dosage form evidence sentences
The ‘How should this medication be used?’ Section and
‘About your treatment’ Section include the detailed
descriptions on drug physical forms and its usage. We
first segmented the section into individual sentences,
and then used a predefined set of patterns (see Table 1)
to extract the sentences E{e1,e 2, ..., ek} that are likely to
mention dosage form information. In the five patterns
P1-P5, both noun and verb variants were allowed. For
example, ‘drug’ in P5 can be ‘drugs’; ‘come’ in P1 and P2
can be ‘comes’.
N e x t ,t oi d e n t i f yR x N o r md o s a g ef o r mf r o mt h o s e
extracted evidence sentences E{e1,e 2, ..., ek},w ef i r s t
added to each sentence ej with the set of segmented
routes R from the title, resulting in an enriched sentence
set E
+{e
+
1,e
+
2, ..., e
+
k}. An example of such enrichment
is shown as below:
￿ Title: Propranolol Oral
￿ After title segmentation: Propranolol [Ingredient]
Oral [Route]
￿ Evidence sentence ek: It also comes as a solution
or concentrate.
￿ After appending title route:I ta l s oc o m e sa sa
solution or concentrate oral
Solid [F4]
Tablet [F4.23] Capsule [F4.4]
Liquids [F2]
Root
Oral Tablet [F4.23.1]
Buccal Tablet
[F4.23.1.1]
Sustained Release Buccal Tablet
[F4.23.1.1.1]
Chewable Tablet
[F4.23.1.2] Disintegrating Tablet 
[F4.23.1.3]
Enteric Coated Tablet 
[F4.23.1.4] Extended Release Tablet
[F4.23.1.5]
Sublingual Tablet
[F4.23.1.6]
Vaginal Tablet [F4.23.2]
Extended Release 
Enteric Coated Tablet
[F4.23.1.4.1]
Extended Release 
Enteric Coated Tablet
[F4.23.1.5.1]
Figure 2 Part of DFtree: Dosage forms organized in a hierarchical tree structure.
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We developed a set of translation rules to map popular
route expressions in AHFS monographs to terms used
in RxNorm DF (TTY = DF; i.e., RxNorm dosage form
concepts). For example, ‘by mouth’ was translated to
‘oral’, into nose’ to ‘nasal’, ‘into ear’ to ‘otic’, ‘on skin’ to
‘topical’,a n d‘in eye’ to ‘ophthalmic’.A ne x a m p l eo f
applying such translation rules is shown as below:
￿ Title: Moxifloxacin
￿ Evidence sentence ek: Moxifloxacin comes as
tablet to take by mouth.
￿ After applying route translation rules: Moxiflox-
acin comes as tablet to take oral.
4 Mapping to RxNorm dosage forms
We turned the evidence sentence after enrichment and
translation into a bag of unique words and performed
Figure 3 Snapshot of AHFS drug monograph ‘Acetaminophen’ in MedlinePlus
®.
Table 1 Patterns for extracting dosage form evidence sentences
Pattern Description Example sentences
P1 [...] come as [...] Sentence contains the phrase ‘come as’ or
its variants.
Ophthalmic ciprofloxacin comes as a solution (liquid) and an ointment to apply
to the eyes.(from monograph ’Ciprofloxacin Ophthalmic’)
P2 [...] come in [...] Sentence contains the phrase ‘come in’ or
its variants.
Golimumab injection comes in prefilled syringes and auto-injection devices.
(from monograph ’Golimumab injection’)
P3 ^[ti] [...] where,
tiÎ I ={ t1,...tq-1}
The first term of sentence is an ingredient
term in title.
Nicotine gum is used by mouth as a chewing gum and should not be
swallowed.(from monograph ’Nicotine gum’)
P4 ^[the]
medication [...]
The subject of sentence is ‘medication’ or
its variants modified by a determiner.
The medication will be added to an intravenous fluid that will drip through a
needle or catheter placed in your vein for 60 minutes two or three times a day.
(from monograph ’Quinupristin and Dalfopristin Injection’)
P5 ^[the]drug [...] The subject of sentence is ‘drug’ or its
variants modified by a determiner.
The drug is taken by mouth in capsule form.(from monograph ’Lomustine’)
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RxNorm DFs (e.g. ‘oral solution’ to ’oral’ and ‘solut’),w e
looked up individual stems from every RxNorm DF in
each sentence.
An RxNorm DF was identified when all its stems were
found in a sentence. In the above ‘Propranolol Oral’
example, because of the enrichment with route informa-
tion from the title, dosage form ‘Oral Solution’ was
identified. For the other ‘Moxifloxacin’ example, ‘Oral
Tablet’ was able to be identified because of translating
‘by mouth’ to ‘oral’.
If more than one DF was found in an evidence sen-
tence, we made use of the DFtree a n dk e p to n l yt h e
ones that are most specific. For example, a sentence
’Darifenacin comes as an extended-release (long-acting)
tablet to take by mouth’ was extracted from the drug
monograph titled as ‘Darifenacin’.B yt r a n s l a t i o n ,‘by
mouth’ was changed to ‘oral’ so that both ‘Oral Tablet’
and ‘Extended Release Tablet’ were identified as candi-
date dosage forms. In this study, we aimed to identify
the most specific dosage forms from each drug mono-
graph. As ‘Extended Release Tablet’ is a child term of
‘Oral Tablet’ i nt h eh i e r a r c h i c a lt r e e( s e eF i g u r e2 ) ,t h e
latter was subsequently removed and only ‘Extended
Release Tablet’ was selected.
Constructing gold and silver standards
To provide a gold standard for evaluation, 100 AHFS
drug monographs were randomly selected for manual
annotation by two annotators (JL and ZL). 40 mono-
graphs were annotated by both annotators with a high
inter-annotator agreement [21] of 97.6%.
To assess our method on the entire set of AHFS
monographs, we relied on its manually curated drug
products (see the bottom part of Figure 3) to construct
silver-standard dosage forms, as each drug product is
known to be associated with one or more dosage forms
in RxNorm. More specifically, the dosage-form silver
standard was derived as: we parsed the ‘Brand name’
Section from each AHFS monograph in XML to extract
a list of brand names and subsequently mapped them to
RxNorm brand names, each of which was then linked to
its dosage form through the semantic branded drug
information in RxNorm. For instance, “Fluoxetine 4
MG/ML Oral Solution [Prozac]“ i sas e m a n t i cb r a n d e d
drug in RxNorm where both dosage form (oral solution)
and brand name (Prozac) are given. By using this
method, a set of dosage forms F{f1,f 2,...fz} were linked to
a given drug monograph and was used as the silver
standard in this study.
In summary, the gold standard was constructed manu-
ally by hand annotating dosage forms in drug mono-
graphs, enabling an unbiased evaluation on a subset of
test data. On the other hand, the silver standard was
constructed automatically from the drug products listed
in drug monographs, enabling a comprehensive evalua-
tion on the entire data set.
Evaluating dosage form identification performance
Precision, Recall and F-Measure were used as evaluation
metrics. Given a drug monograph, Precision is the frac-
tion of correctly identified dosage forms over the entire
set of identified dosage forms D; Recall is the fraction of
correctly identified dosage forms over the gold-stan-
dard/silver-standard dosage form set F;a n dF-Measure
is the harmonic mean of precision and recall. The over-
all performance is computed as the macro-average of
the three evaluation metrics. In our primary evaluation,
for a prediction to be considered as a true positive, it
must exactly match the corresponding answer in the
gold or silver standard
1.
Precision =
|D ∩ F|
|D|
; Recall =
|D ∩ F|
|F|
;
F − Measure =
2 × Precision × Recall
Precision + Recall
To evaluate our method performance, we computed
all three evaluation metrics against the gold and silver
standard respectively. Furthermore, we compared our
method with a baseline approach to assess the contribu-
tion of the manually developed patterns and translation
rules. In the baseline approach, an RxNorm dosage form
was identified when all its terms were found in the
‘How should this medicine be used?’ Section.
Results
Result overview
In our experiments, we used the datasets consisting of
1095 AHFS drug monographs (as of January 2011). We
randomly divided all 1095 AHFS monographs into two
halves, one for development and the other for testing. It
is important to note that all the patterns (e.g.,f o rf i n d -
ing evidence sentence) and rules (e.g.,f o rs e g m e n t i n g
titles) used in this work were developed based on our
examination of the monographs in the development set.
That is, the monographs in the test set were used for
testing purposes only.
For the 100 annotated drug monographs in the gold
standard, 55 were from the development set and 45
from the test set, with an average of 1.55 dosage forms
per drug monograph.
In the silver standard construction, we found 80
dosage forms for 933 monographs among all 1095
monographs. For the remaining 162 monographs that
we failed to find their dosage forms, 122 were due to
the lack of ‘Brand names’ Sections (e.g., monograph
‘Dicloxacillin’); 20 were due to the failure of brand
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®’ in monograph ‘Stron-
tium-89 Chloride’); and 20 were due to missing links
between dosage form and brand names in RxNorm (e.g.,
‘Alphagan P
®’ in monograph ‘Brimonidine Ophthalmic’).
After removing those 162 monographs, we have 462 in
development set and 471 in test set. On average, each
monograph is linked to 2.09 and 1.97 dosage forms in
development and test set, respectively. As shown in Fig-
ure 4, the two halves exhibit similar drug dosage forms
distributions.
We assessed our identification results against the gold
standard and silver standard on both development and
test set. Given a drug monograph, Precision, Recall and
F-Measure were calculated. Table 2 shows the results of
performance comparison on the mean, standard devia-
tion, median, and interquartile range of these three
metrics. As can be seen, the performance of our method
on the test set (F-Measure of 0.85) resembles that on
the development set (F-Measure of 0.84), which
indicates that the rules and patterns learned from the
development set succeeded in the test set.
On the test set, our method achieved overall macro-
averaged (mean) Precision of 80%, Recall of 98%, and F-
Measure of 85% on the gold standard, as well as Preci-
sion of 70%, Recall of 81%, and F-Measure of 71% on
the silver standard. The decrease in performance on the
silver standard is mainly due to its incompleteness and
noisiness. Taking the monograph ‘Chlordiazepoxide’ as
an example, based on the sentence ‘Chlordiazepoxide
comes as a tablet and capsule to take by mouth’,t h e
two dosage forms ‘Oral Tablet’ and ‘Oral Capsule’ were
manually included to the gold standard for this drug
monograph. By contrast, because ‘Librium
®’ is one of
the brand names listed in this monograph, its two
dosage forms ‘Injectable Solution’ and ‘Oral Capsule’
were automatically included to the silver standard. As a
result, in this case the silver standard misses a true
dosage form ‘Oral Tablet’ but rather includes a false
one ‘Injectable Solution.’ Hence, lower system perfor-
mance is expected on the silver standard than the gold
standard.
Figure 5 shows the results of performance comparison
between our method and the baseline method on the
test set. The macro-averaged Precision, Recall and F-
Measure were calculated against both the gold and silver
standards. As shown in Figure 5, our method achieved
significantly better performance than the baseline
method. These results indicate that those manually
developed heuristic rules and patterns are important for
achieving good performance.
Error analysis
From our evaluation based on both the gold and silver
standards, we can see that our method performed well
on the entire monograph collection. Only for very small
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Figure 4 Comparison of dosage form distribution on
development and test set.
Table 2 Overview of dosage form identification performance
Gold standard (100) Silver Standard (933)
Development (55) Test(45) Development (462) Test(471)
Precision Mean 0.81 0.80 0.75 0.70
Standard deviation 0.30 0.27 0.27 0.31
Median 1.00 1.00 0.75 0.67
Interquartile range 0.38 0.50 0.50 0.50
Recall Mean 0.93 0.98 0.82 0.81
Standard deviation 0.24 0.09 0.27 0.31
Median 1.00 1.00 1.00 1.00
Interquartile range 0.00 0.00 0.40 0.33
F-Measure Mean 0.84 0.85 0.74 0.71
Standard deviation 0.27 0.20 0.23 0.27
Median 1.00 1.00 0.67 0.67
Interquartile range 0.24 0.33 0.33 0.35
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dosage forms.
One type of error comes from the fact that we did not
take into account a term’s relative position in the sen-
tence. For example, ‘Cyclobenzaprine comes as a tablet
a n da ne x t e n d e dr e l e a s ec a p s u l et ot a k eb ym o u t h .’ is
t h ed o s a g ef o r me v i d e n c es e n t e n c ee x t r a c t e df r o m
monograph ‘Cyclobenzaprine’. As our method repre-
sented it as a bag of words, in addition to the correct
dosage form ‘Extended Release Capsule’, an incorrect DF
‘Extended Release Tablet’ was also identified. Hence, the
Precision, Recall and F-Measure decreased to 50% in
this case.
For those monographs where we failed to identify any
correct dosage forms, one main reason is because there
is neither ‘How should this medication be used?’ nor
‘About your treatment’ Section in these monographs (e.
g., ‘Polio Vaccine’ and ‘Typhoid Vaccine’). Thus, our
method failed to identify any evidence sections or sen-
tences from these monographs. As a result, empty
results were returned by our method in these cases.
Discussion
Practical implications of this research
We successfully developed an automatic method to
identify dosage forms from full-length AHFS drug
monographs and further normalize them to RxNorm
concepts. By doing so, our method can contribute to
several real world applications with regards to the AHFS
drug monographs and its related resources:
1 Through RxNorm, our method can automatically
retrieve other drug attributes and further link a pre-iden-
tified drug to other medical terminologies. For instance,
after normalizing a drug mention to RxNorm based on
its ingredient and dosage form, one can easily retrieve
more drug attributes in RxNorm such as National Drug
Code (NDC) and information on drug prescription and
human/veterinarian use. Additionally, RxNorm is part of
the Unified Medical Language System
® (UMLS
®)[22]
which brings together many health and biomedical voca-
bularies and standards (134 sources in 2011AA release)
to enable interoperability between computer systems. If a
drug has an RxNorm identifier, it can be further linked
to other resources in UMLS such as National Drug File-
Reference Terminology (NDF-RT) [23] and Medical Sub-
ject Headings (MeSH) [24].
2 Through RxNorm, our method can help AHFS edi-
tors update and revise their drug page information.
Because RxNorm is updated on a regular basis, our
method allows to use the latest RxNorm to identify any
new or different information about a drug in an AHFS
page. Taking the drug ‘Vardenafil’ for example, we were
able to identify ‘Oral Tablet’ from its full-text mono-
graph. Through RxNorm, we found two drug products
(”Levitra“ and “Staxyn“) both containing active ingredi-
ent ‘Vardenafil’ and made as oral tablet. However, the
drug brand name “Staxyn“ is currently missing in its
corresponding monograph due to the fact that it is a
new drug approved in June, 2010 [25], while the ‘Varde-
nafil’ monograph was last updated in September, 2008.
3 Our method can help more accurately link drug
monographs to other related resources. At present, the
AHFS monographs in MedlinePlus have been linked
with other NLM resources such as ClinicalTrial.gov [2]
and NLM Drug Information Portal [26] through ingredi-
ents. However, drugs with the same ingredient but in
different dosages forms may need to be distinguished
and linked differently. For example, there are four Diclo-
fenac related monographs in MedlinePlus (titled as
‘Diclofenac’, ‘Diclofenac Transdermal’, ‘Diclofenac
Ophthalmic’,a n d‘Diclofenac Topical’ respectively). In
this case, instead of linking them to the same set of clin-
ical trials, our method enables us to link them to differ-
ent trials where drugs of specific dosage forms were
studied.
Limitations of our study
This study has two limitations. First, although our rule-
based method has shown robust and quite satisfactory
results on the blinded test set, it was specifically devel-
oped for finding dosage forms in the AHFS drug mono-
graphs. For example, the titles of AHFS drug
monographs followed the “ingredient + route” pattern.
Therefore, when applied to other types of documents,
extra patterns or rules may be needed.
Second, to evaluate method performance on the entire
set, we constructed a silver standard based on the
assigned drug products. Although this computed “silver
standard” enabled us to perform a feasible large-scale
evaluation, its own accuracy (as shown in the ‘Result
overview’ Section) may underestimate the performance
of our method.
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Figure 5 Comparison of our dosage form identification
method with baseline.
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In this study, we presented a rule-based method to auto-
matically identify and normalize a medication’sd o s a g e
forms to a standardized nomenclature (i.e., RxNorm dosage
forms). Our rules were independently developed on the
development set. For evaluation, we manually annotated
dosage forms for ~10% of drug monographs (the gold stan-
dard), on which our method achieved macro-averaged Pre-
cision of 80%, Recall of 98% and F-Measure of 85%. In
addition, for a larger scale evaluation on the entire test
data, we derived a silver standard based on the known
drug products associated with the drug monographs.
Accordingly, our method achieved Precision of 70%, Recall
of 81% and F-Measure of 71%. As discussed, the perfor-
mance numbers on the silver standard are likely to be
underestimated due to the quality of the silver standard.
Our method has been successfully applied to a large
set of drug monographs as a step toward providing
users with integrated access to multiple drug-related
resources. It may also be helpful for monograph editors
to revise and update drug information for improving the
quality of consumer health information on medications.
Finally, our results illustrate that the rules and patterns
developed in this work are critical for achieving good
performance. We expect our method to be beneficial to
applications with regards to the AHFS drug monographs
and its related resources.
Endnotes
1No significant difference in evaluation results was
found when considering the hierarchical relationships
between dosage forms when comparing our predictions
with the answers.
Additional material
Additional file 1: A complete set of DFtree information.
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